THE MICROBIOME FACTOR IN ONCOLOGY: ENHANCING DRUG EFFICACY AND REDUCING ADVERSE EFFECTS THROUGH MICROBIOTECHNOLOGICAL MODULATION

In recent years, the gut microbiome has been increasingly recognized as a key modifiable
determinant of both the efficacy and safety of anticancer therapy. Growing clinical and experimental
evidence indicates that microbial community structure and, more importantly, functional capacity can
shape systemic immune tone, inflammatory signaling, and host–microbe metabolic outputs (including
short-chain fatty acids, tryptophan-derived metabolites, and bile acid transformation). Through these
pathways, the microbiome may influence tumor immune microenvironment features and the
likelihood of response or resistance to modern treatments, particularly immune checkpoint inhibitors
targeting PD-1/PD-L1 and CTLA-4. In parallel, the microbiome can contribute to treatment-related 
toxicity by modulating drug metabolism and mucosal immunity, thereby affecting the risk and
severity of immune-related adverse events (irAEs) and gastrointestinal complications. This article
synthesizes current mechanistic concepts and translational findings linking the microbiome to
oncologic outcomes and evaluates microbiotechnology-driven strategies for targeted microbiome
modulation, including fecal microbiota transplantation, live biotherapeutic products (defined
microbial consortia), prebiotic and postbiotic interventions, metabolite-oriented approaches, and
selective inhibition of specific bacterial enzymes as a rational route to reduce toxicity while
preserving anticancer activity. Particular attention is paid to practical barriers to implementation—
standardization, biosafety, reproducibility, regulatory requirements, and major confounders such as
antibiotic exposure, diet, and concomitant medications—which complicate causal inference and limit
broad clinical adoption. Overall, the evidence supports the promise of personalized, biomarker
informed microbiome modulation as an adjunct strategy to enhance therapeutic benefit and mitigate
adverse effects, provided that efficacy and safety are confirmed in well-controlled clinical trials.